Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | TranspoCART19 |
| Trade Name | |
| Synonyms | Transpo-CART19|Transpo CART19 |
| Drug Descriptions |
TranspoCART19 is a transposon-based chimeric antigen receptor (CAR) T-cell therapy targeting CD19 that contains TNFRSF9 (4-1BB) and CD3zeta endodomains fused to a truncated human epidermal growth factor receptor (hEGFRt) as a safety switch, which potentially enhances antitumor immune response and inhibits tumor growth (PMID: 40034423). |
| DrugClasses | CD19 Immune Cell Therapy 72 |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| TranspoCART19 | TranspoCART19 | 0 | 1 |